Chloramphenicol is a substrate for a novel nitroreductase pathway in Haemophilus influenzae.
The p-nitroaromatic antibiotic chloramphenicol has been used extensively to treat life-threatening infections due to Haemophilus influenzae and Neisseria meningitidis; its mechanism of action is the inhibition of protein synthesis. We found that during incubation with H. influenzae cells and lysates, chloramphenicol is converted to a 4-aminophenyl allylic alcohol that lacks antibacterial activity. The allylic alcohol moiety undergoes facile re-addition of water to restore the 1,3-diol, as well as further dehydration driven by the aromatic amine to form the iminoquinone. Several Neisseria species and most chloramphenicol-susceptible Haemophilus species, but not Escherichia coli or other gram-negative or gram-positive bacteria we examined, were also found to metabolize chloramphenicol. The products of chloramphenicol metabolism by species other than H. influenzae have not yet been characterized. The strains reducing the antibiotic were chloramphenicol susceptible, indicating that the pathway does not appear to mediate chloramphenicol resistance. The role of this novel nitroreductase pathway in the physiology of H. influenzae and Neisseria species is unknown. Further understanding of the H. influenzae chloramphenicol reduction pathway will contribute to our knowledge of the diversity of prokaryotic nitroreductase mechanisms.
Smith
Arnold L
AL
Microbial Pathogens Program, Seattle Biomedical Research Institute, Seattle, WA 98109-5219, USA. arnold.smith@sbri.org
Erwin
Alice L
AL
Kline
Toni
T
Unrath
William C T
WC
Nelson
Kevin
K
Weber
Allan
A
Howald
William N
WN
D000900:Anti-Bacterial Agents / Q000378:metabolism* / Q000494:pharmacology; D001426:Bacterial Proteins / Q000378:metabolism; D002701:Chloramphenicol / Q000378:metabolism* / Q000494:pharmacology; D006190:Haemophilus / Q000145:classification / Q000187:drug effects / Q000201:enzymology / Q000254:growth & development; D006193:Haemophilus influenzae / Q000187:drug effects / Q000201:enzymology* / Q000254:growth & development; D006801:Humans; D008826:Microbial Sensitivity Tests; D009343:Neisseria / Q000145:classification / Q000187:drug effects / Q000201:enzymology / Q000254:growth & development; D009601:Nitroreductases / Q000378:metabolism*; D010084:Oxidation-Reduction; D013379:Substrate Specificity
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002701:Chloramphenicol; D009601:Nitroreductases